Non-alcoholic steatohepatitis, also known as NASH, is a growing concern in the medical community. This disease is characterized by a combination of inflammation and fat accumulation in the liver which can ultimately result in fibrosis, cirrhosis, liver failure, or liver cancer. In a recent article discussing this disease, Taconic Biosciences's Dr. Megan MacBride comments that commercially-available mouse models that develop the symptoms of NASH can have great influence on the development of new treatments for this condition:
"There are currently no FDA-approved medicines for the treatment of non-alcoholic steatohepatitis, but researchers hope a new mouse model will speed the drug discovery process.
Non-alcoholic steatohepatitis, also known as NASH, is a severe form of non-alcoholic fatty liver disease (NAFLD) that is characterized by a combination of inflammation and fat accumulation in the liver. Most people with NASH are between the age of 40 and 60 and women are more likely to get the disease than men."
Read the whole article at: laboratoryequipment.com
"There are currently no FDA-approved medicines for the treatment of non-alcoholic steatohepatitis, but researchers hope a new mouse model will speed the drug discovery process. Non-alcoholic steatohepatitis, also known as NASH, is a severe form of non-alcoholic fatty liver disease (NAFLD) that is characterized by a combination of inflammation and fat accumulation in the liver. Most people with NASH are between the age of 40 and 60 and women are more likely to get the disease than men."